AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04709900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT angiography, FFR-CT and stress CT myocardial perfusion
Description: The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
Study NCT04932876 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS - COV 2 VACCINE
Description: Vaccination for SARS - COV 2
Study NCT06487000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EC-18
Description: oral administration, QD
Study NCT04545151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil SR 120 mg
Description: For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily
Study NCT04545151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily
Study NCT05849298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
Study NCT05849298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA517
Description: Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
Study NCT05849298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F 18
Description: Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
Study NCT05849298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARPI
Description: Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
Study NCT05849298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: as prescribed by the local investigator
Study NCT04109014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FASTLANE II
Description: The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions.
Study NCT05632835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Description: 3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..
Study NCT05632835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guidance
Description: The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
Study NCT05849298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: as prescribed by the local investigator
Study NCT05361655 — intervention group
Intervention type: DRUG
Intervention: Palbociclib + an aromatase inhibitor
Description: Palbociclib + an aromatase inhibitor therapy
Study NCT05361655 — intervention group
Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor therapy
Study NCT05684406 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping by Real Time PCR
Study NCT06142994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Atusin CAP
Description: This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
Study NCT06142994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
Study NCT06580535 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: Blood sample taking from patient for tissue culture
Study NCT06175026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health messages
Description: Participants view messages about the health impacts of certain dietary substitutions.
Study NCT06175026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental messages
Description: Participants view messages about the environmental impacts of certain dietary substitutions.
Study NCT06175026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and environmental messages
Description: Participants view messages about the health and environmental impacts of certain dietary substitutions.
Study NCT06175026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral messages
Description: Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
Study NCT04974138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Study NCT04974138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and folic acid
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
Study NCT04974138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine placebos
Description: An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
Study NCT05182567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 1)
Description: GLS-5310 DNA plasmid vaccine
Study NCT05182567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 2)
Description: GLS-5310 DNA plasmid vaccine
Study NCT05182567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 3)
Description: GLS-5310 DNA plasmid vaccine
Study NCT05182567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 4)
Description: GLS-5310 DNA plasmid vaccine
Study NCT05072457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roger On microphone
Description: Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids
Study NCT05072457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roger Select microphone
Description: Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
Study NCT04193397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Resistance training program performed during 6 months, 3 sessions per week
Study NCT04974138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine-folic acid placebos
Description: An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
Study NCT06431841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0,025%
Description: Atropine 0,025% (1 drop per day)
Study NCT06431841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 0,025%
Description: Atropine 0,025% (1 drop per day)
Study NCT06431841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIMS Lenses
Description: Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.
Study NCT06431841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal lenses
Description: Use of monofocal lenses.
Study NCT06270316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-191
Description: A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with FD.
Study NCT05545514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
Study NCT05545514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
Study NCT06098729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Exercise
Description: A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
Study NCT04761198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etigilimab
Description: IV infusion of IV etigilimab every 2 weeks
Study NCT05731154 — intervention group
Intervention type: OTHER
Intervention: taking periorbital selfie images using smartphones
Description: taking periorbital selfie images using smartphones
Study NCT04712435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
Study NCT04712435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
Study NCT05304637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTEAR100 treatment
Description: Vibratory energy to the external nasal nerve
Study NCT01304446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
Description: The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
Study NCT04761198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks
Study NCT06389760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: When combined with the mFOLFIRINOX regimen, nimotuzumab (nimo) will be administered at a dose of 400mg on Day 1 and 15 of a 28-day cycle (6 cycles). When combined with the GX regimen, nimotuzumab will be given at 400mg on Day 1 and 8 of a 21-day cycle (8 cycles).
Study NCT06389760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
Study NCT06389760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX
Description: Patients will receive GX regimen as follows: Gemcitabine 1000 mg/m2 on Day 1 and 8 of a 21-day cycle; capecitabine 2000 mg/m2 on d1-14 a 21-day cycle(8 cycles).
Study NCT05562479 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sars Cov 2 infection
Description: Donors recovered from Sars Cov 2 Infection
Study NCT05562479 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sars Cov 2 vaccination
Description: Egg Donors vaccinated
Study NCT04560166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab and GM-CSF in combination with irinotecan and temozolomide
Description: * Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)
Study NCT04649502 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin in combination with doxycycline
Study NCT04649502 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in combination with doxycycline
Study NCT05650164 — intervention group
Intervention type: DRUG
Intervention: avelumab
Description: as provided in real world practice
Study NCT05650164 — intervention group
Intervention type: DRUG
Intervention: axitinib
Description: as provided in real world practice
Study NCT05065489 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06369779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TM Fill in combination with TM Flow
Description: The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
Study NCT05206253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: Nutritional supplementation during a 12 week resistance training program
Study NCT05206253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein powder
Description: Nutritional supplementation during a 12 week resistance training program
Study NCT05206253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: Nutritional supplementation during a 12 week resistance training program
Study NCT05500339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-health App
Description: Pregnant women receive the App designed for the support of the first 1000 days of life
Study NCT05500339 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: Pregnant women receive standard supportive and educational methods.
Study NCT05307380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional pain scale
Description: French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
Study NCT05797103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands
Description: Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
Study NCT06169514 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05001724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is 5 milligram per kilogram, every 3 weeks.
Study NCT05001724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is RP3D milligram per day, every day.
Study NCT05001724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is 75 milligram per Square meter, every 3 weeks.
Study NCT05095805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: additional weight-bearing exercise
Description: Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
Study NCT05095805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard weight-bearing exercise
Description: conventional training for fitting of initial prosthesis
Study NCT06384586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo shot
Description: 60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
Study NCT06384586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo shot
Description: 60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
Study NCT06384586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional energy shot
Description: 60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
Study NCT06384586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Functional energy shot
Description: 60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
Study NCT05326022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy
Description: Microcurrent therapy
Study NCT05326022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Laser therapy
Study NCT05326022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: Medical therapy
Study NCT05662553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB guided MWA combined with VATS
Description: ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode.
Study NCT05662553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential surgery
Description: Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
Study NCT05492071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Vibration Application Following Flow Mediated Dilation
Description: Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
Study NCT05492071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow mediated dilation
Description: Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
Study NCT04884659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding arm
Description: 80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours